Journal
ONCOTARGET
Volume 7, Issue 21, Pages 30511-30522Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.8852
Keywords
cancer stem cell; ovarian cancer; cisplatin; NANOG
Categories
Funding
- Cleveland Clinic VeloSano Bike Race
- Cleveland Clinic Foundation
- Clinical and Translational Science Collaborative of Cleveland [UL1TR000439]
- Case Comprehensive Cancer Center [P30 CA043703]
- NCI [CA191263]
- National Institutes of Health [CA191263, NS089641, NS083629, CA157948]
- Sontag Foundation
- American Cancer Society
- Blast GBM
- Case Comprehensive Cancer Center
Ask authors/readers for more resources
The mainstay of treatment for ovarian cancer is platinum-based cytotoxic chemotherapy. However, therapeutic resistance and recurrence is a common eventuality for nearly all ovarian cancer patients, resulting in poor median survival. Recurrence is postulated to be driven by a population of self-renewing, therapeutically resistant cancer stem cells (CSCs). A current limitation in CSC studies is the inability to interrogate their dynamic changes in real time. Here we utilized a GFP reporter driven by the NANOG-promoter to enrich and track ovarian CSCs. Using this approach, we identified a population of cells with CSC properties including enhanced expression of stem cell transcription factors, self-renewal, and tumor initiation. We also observed elevations in CSC properties in cisplatin-resistant ovarian cancer cells as compared to cisplatin-naive ovarian cancer cells. CD49f, a marker for CSCs in other solid tumors, enriched CSCs in cisplatin-resistant and -naive cells. NANOG-GFP enriched CSCs (GFP+ cells) were more resistant to cisplatin as compared to GFP-negative cells. Moreover, upon cisplatin treatment, the GFP signal intensity and NANOG expression increased in GFP-negative cells, indicating that cisplatin was able to induce the CSC state. Taken together, we describe a reporter-based strategy that allows for determination of the CSC state in real time and can be used to detect the induction of the CSC state upon cisplatin treatment. As cisplatin may provide an inductive stress for the stem cell state, future efforts should focus on combining cytotoxic chemotherapy with a CSC targeted therapy for greater clinical utility.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available